Home » Key Scientific Articles » Personalized therapy with probiotics from the host by TripleA.

Personalized therapy with probiotics from the host by TripleA.

Kort R.

Trends Biotechnol. 2014 Jun;32(6):291-3.

TNO Microbiology and Systems Biology, Zeist, The Netherlands; VU University Amsterdam, Molecular Cell Physiology, Amsterdam, The Netherlands. Electronic address: [email protected]

 

Abstract

Currently, all probiotics available on the market have been obtained by selection and cultivation of a limited number of microorganisms from a relatively small number of sources. In many cases a bacterial strain is isolated from a dairy product or a human stool sample, tested for safety and specific health benefits, and administered as a therapeutic agent or functional food to many different individuals. Many of these current probiotic species constitute a low proportion of those naturally present in the targeted ecosystems of the human body.

Go To PubMed

 

Significance Statement:

Currently, all probiotics available on the market have been obtained by selection and cultivation of a limited number of microorganisms from a relatively small number of sources. In many cases a bacterial strain is isolated from a dairy product or a human stool sample, tested for safety and specific health benefits, and administered as a therapeutic agent or functional food to many different individuals. Many of these current probiotic species constitute a very low proportion of those naturally present in the targeted ecosystems of the human body. Besides, their physiological impact after a period of administration may be limited by their inability to colonize the human body for an extended period of time. Evidence accumulates that the genetic makeup of the host is a crucial factor for facilitating the colonization of beneficial bacteria in the human body. Therefore, treatment of a patient suffering from a recurring infection could be more effective with one or more of the patient’s own species. This innovation would fit into today’s development of personalised therapeutics. The microbial population isolated from the infected site of the body can be enriched for bacteria, which are associated with a healthy microbiome. The ex-vivo-enriched-sample can be used for therapeutic purposes and may be more efficacious than probiotics administered according to the one-size-fits-all concept. This innovative method is designated to TripleA, referring to the three consecutive steps involved, including Acquirement of the sample, Alteration of the microbial composition and Administration of the enriched sample.

 

2101_Illustratie_TNO_EB